In this study, we investigated two key contributors to this phenomenon: (1) the increased cancer aggressiveness driven by elevated prolactin (PRL) levels during pregnancy and (2) the limited treatment options available to pregnant CRC patients. This evidence concerns the gene PRL and cancer.